HSF1 and cancer: Moreover, overexpression of HSP72 (HSP70) induced by bortezomib was found to limit the anti-cancer effects of bortezomib, and combination therapy with HSF1 inhibitor was effective in enhancing bortezomib-mediated cancer cell death [181].